Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib vs Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer.

Rachel N Grisham Ignace Vergote Susana Banerjee Esther Drill Elsa Kalbacher Mansoor Raza Mirza Ignacio Romero Peter Vuylsteke Robert L Coleman Felix Hilpert Amit M Oza Anneke M Westermann Martin K Oehler Sandro Pignata Carol Aghajanian Nicoletta Colombo David Cibula Kathleen M Moore Josep M Del Campo Regina Berger Christian Marth Jalid Sehouli David M O'Malley Cristina Churruca Gunnar B Kristensen Andrew R Clamp John Farley Gopakumar V Iyer Isabelle Ray Coquard Bradley J Monk

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Although this hypothesis-generating analysis is limited by multiple testing, higher RRs and longer PFS were seen in patients with LGSOC treated with binimetinib, and to a lesser extent in those treated with PCC, who harbored MAPK pathway alterations. Somatic tumor testing should be routinely considered in patients with LGSOC and utilized as a future stratification factor.

Keyphrases